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ABSTRACT
Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce 
its efficacy in hepatocellular carcinoma (HCC) treatment. Drug-resistant cancer 
cells frequently exhibit sphingolipid dysregulation, reducing chemotherapeutic 
cytotoxicity via the induction of ceramide-degrading enzymes. However, the 
role of ceramide in sorafenib therapy and resistance in HCC has not been clearly 
established. Our data reveals that ceramide-modifying enzymes, particularly 
glucosylceramide synthase (GCS), are upregulated during sorafenib treatment in 
hepatoma cells (HepG2 and Hep3B), and more importantly, in sorafenib-resistant 
cell lines. GCS silencing or pharmacological GCS inhibition sensitized hepatoma 
cells to sorafenib exposure. GCS inhibition, combined with sorafenib, triggered 
cytochrome c release and ATP depletion in sorafenib-treated hepatoma cells, 
leading to mitochondrial cell death after energetic collapse. Conversely, genetic GCS 
overexpression increased sorafenib resistance. Of interest, GCS inhibition improved 
sorafenib effectiveness in a xenograft mouse model, recovering drug sensitivity of 
sorafenib-resistant tumors in mice. In conclusion, our results reveal GCS induction 
as a mechanism of sorafenib resistance, suggesting that GCS targeting may be a 
novel strategy to increase sorafenib efficacy in HCC management, and point to 
target the mitochondria as the subcellular location where sorafenib therapy could 
be potentiated.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common liver cancer and the end stage of chronic liver 
disease [1]. Its prevalence is expected to rise due to the 
escalating increase of non-alcoholic fatty liver disease 
associated to obesity and metabolic syndrome, and the 
incidence of HCV [2, 3]. HCC is often diagnosed in an 
advanced stage characterized by resistance to current 
therapy, when curative strategies are no longer applicable. 
The establishment of the multikinase inhibitor sorafenib 
as the standard of care has opened a window of hope for 
HCC patients with very poor prognosis [3]. However, 
this promising systemic treatment has limited survival 
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benefits with low rates of tumor response, probably due 
to the existence of primary and acquired drug resistance 
mechanisms [4, 5]. Several drugs are now in the pipeline 
for HCC application, either alone or in combination with 
sorafenib, but the lack of positive results complicates 
their clinical application. Additionally, effective therapy 
combinations may reveal novel targets of treatment for 
HCC [4–6].
Ceramide is a bioactive sphingolipid generated 
in response to a wide range of stimuli, including 
chemotherapeutic agents, which triggers cell death [7]. 
Transient or sustained ceramide generation (Suppl. Fig. 
1), either by sphingomyelinases activation or de novo 
synthesis, respectively [7, 8], can be limited by the 
concurrent activation of ceramide-degrading enzymes, 
which reduce the efficacy of drug therapy on tumor 
cells [8, 9]. For instance, glucosylceramide synthase 
(GCS) catalyzes the generation of glucosylceramide 
from ceramide while ceramidases (CDases) deacylate 
ceramide to sphingosine, which is then phosphorylated 
to sphingosine-1-phosphate by sphingosine kinases. Both 
pathways have been characterized in drug-resistance 
as protective mechanisms triggered by tumor cells after 
cancer treatment [8, 10, 11]. In liver cancer, increasing 
intratumoral ceramide levels with nanoliposomal 
administration has been used as a strategy in the treatment 
of HCC [12], while targeting acid CDase (ACDase) 
potentiated the cytotoxic effect of daunorubicin in 
hepatoma cells [13]. Regarding sorafenib action, recent 
data has shown the efficacy of combining sorafenib 
with recombinant acid sphingomyelinase, a ceramide-
generating enzyme, in experimental liver cancer [14], 
or with nanoliposomal ceramide in melanoma or breast 
cancer [15]. These findings have proposed a role for 
sphingolipids in sorafenib toxicity [16], but a detailed 
analysis of ceramide metabolism in vitro and in vivo HCC 
models after sorafenib treatment has not been previously 
reported.
Our data indicate that, although sorafenib alters the 
sphingolipidic metabolism in hepatoma cells via ASMase 
activation, ceramide toxicity is partially reduced by the 
simultaneous induction of ceramide-eliminating enzymes, 
in particular GCS. Moreover, pharmacological or genetic 
GCS antagonism sensitized hepatoma cells to sorafenib 
by a caspase-independent mitochondrial-dependent 
mechanism. Moreover, GCS is upregulated in resistant 
hepatoma cells after long-term exposure to sorafenib, 
pointing to GCS targeting as an effective approach to re-
sensitize tumor cells to sorafenib. Therefore, our results 
validate the interest of ceramide-focused strategies to 
increase sorafenib effectiveness in HCC and confirm 
mitochondria as the subcellular site responsible for these 
effects.
RESULTS
Sorafenib increases ceramide levels and the 
expression of enzymes involved in ceramide 
metabolism in Hep3B cells
Despite several evidences showing the influence 
of ceramide-related compounds in sorafenib efficacy 
[14, 15], the effect of sorafenib on ceramide metabolism 
has not been evaluated. Among critical sphingolipidic 
genes (Suppl. Fig. 1), we found that overnight sorafenib 
exposure increased expression of genes responsible 
for ceramide production (Table 1) by sphingomyelin 
hydrolysis (acid sphingomyelinase, ASMase) or de novo 
synthesis (serine palmitoyl transferase, SPT, ceramide 
synthase 2, CerS2). In parallel, genes involved in ceramide 
modification via ceramidase degradation (acid ceramidase, 
ACDase, and sphingosine kinase 1, SK1) or glycosylation 
(glucosylceramide synthase, GCS) were also increased. 
Moreover, in another hepatoma cell line, HepG2, sorafenib 
also increased ceramide formation through ASMase and 
glycosylation via GCS (Suppl. Table 1).
Table 1: mRNA levels of main sphingolipidic enzymes in Hep3B cells after sorafenib exposure 
Sorafenib (μM) 0 2.5 5 10
ASMase 1.00±0.32 2.05±0.66 * 2.39±0.22 * 1.53±0.60
NSMase 1.00±0.10 0.90±0.20 1.10±0.20 1.15±0.15
ACDase 1.00±0.07 2.07±0.59 * 2.70±0.37 * 1.33±0.56
NCDase 1.00±0.11 0.85±0.16 0.95±0.23 1.05±0.20
CerS2 1.00±0.35 1.63±0.54 1.85±0.70 2.65±0.69 *
CerS4 1.00±0.21 1.10±0.09 1.20±0.29 1.30±0.18
GCS 1.00±0.09 1.65±0.73 2.46±0.34 * 4.01±0.69 *
SPT 1.00±0.13 1.59±0.54 2.10±0.33 * 1.97±0.59 *
SK1 1.00±0.37 1.40±0.35 1.64±0.45 0.77±0.51
Hep3B cells were exposed to increasing doses of sorafenib (2.5, 5, 10 μM) for 16 hours and main enzymes in ceramide 
metabolism analyzed by RT-PCR. (n=3). *, p<0.05 vs. control.
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Rapid changes in ceramide concentration due to 
ionizing radiation or chemotherapeutic agents are induced 
by ASMase stimulation, while sustained ceramide 
increase via de novo synthesis occurs through activation 
of ceramide synthases, such as CerS2 and CerS4, which 
exhibit predominant liver expression [20, 21]. Time-
response analysis in Hep3B cells showed both increases 
(Figure 1A), in ASMase and in de novo ceramide 
synthesis (SPT and CerS2). Moreover, sorafenib induced 
the expression of GCS and ACDase, which metabolize 
ceramide, as well as SK1. These effects were accompanied 
by changes in ceramide levels upon sorafenib treatment. 
Ceramide increased dose-dependently, being significant 
for all doses (from 2.5 to 20 μM) after 4 h of sorafenib 
exposure (Figure 1B).
Pharmacologic inhibition of sphingolipid 
enzymes modulates sorafenib-induced toxicity in 
hepatoma cells
To examine the role of the ceramide production/
degradation pathways in sorafenib cytotoxicity, we 
administered sphingolipid inhibitors combined with 
sorafenib in hepatoma cells (Suppl. Fig. 1). First, we 
used myriocin (MYR, 5 μM), which targets ceramide 
de novo biosynthesis by inhibiting SPT; and imipramine 
(IMIP, 15 μM), tricyclic antidepressant and effective 
ASMase inhibitor [22], to block ceramide generation 
from the sphingomyelin pathway, at doses that caused 
no effect in hepatoma cell growing. Imipramine reduced 
significantly sorafenib-induced cell death (Figure 1C), 
while myriocin (Figure 1D) or fumonisin B1 (FB1) (data 
not shown), another blocker of the de novo pathway [22], 
caused no effect in sorafenib action, further confirming 
a contributory role of ASMase activation in sorafenib 
toxicity [14].
To examine if forcing ceramide accumulation could 
increase sorafenib cytotoxicity in vitro, we tested cell 
viability after inhibition of ACDase with NOE (Figure 
2A), or GCS with PDMP in sorafenib-treated Hep3B cells 
(Figure 2B). Cell death was augmented significantly upon 
inhibition of GCS and ACDase, and similar effects were 
observed with PDMP but not NOE in sorafenib-exposed 
HepG2 cells (Suppl. Fig. 2). Of note, neither PDMP nor 
NOE alone caused damage to primary mouse hepatocytes 
as previously reported [13, 18], having no significant 
effect on sorafenib toxicity in normal hepatocytes (data 
not shown). Moreover, changes in ceramide content after 
inhibition of ACDase with NOE or GCS with PDMP 
were confirmed in sorafenib-treated Hep3B cells (Figure 
2C). Remarkably, GCS inhibition was more effective 
increasing ceramide levels after sorafenib exposure, in 
line with greater sorafenib toxicity induced by PDMP, 
and further demonstrating the upregulation of ceramide 
metabolism after sorafenib exposure. Interestingly, we 
detected GCS but not in ACDase induction by sorafenib 
Figure 1: Sorafenib administration to hepatoma cells induces changes in ceramide metabolism. A. Time-course analysis 
of mRNA levels of main sphingolipidic enzymes in Hep3B cells exposed to sorafenib (5μM). B. Ceramide levels were quantified in Hep3B 
cells treated with increased doses of SOR (2.5, 5, 10 and 20 μM) during different times of incubation, after lipid extraction, TLC running 
and PhosphoImager quantification. C. and D. Cell viability of Hep3B cells, preincubated (30 min) with imipramine (IMIP, 15 μM) or 
myriocin (MYR, 5 μM), and treated with sorafenib for 16 h. (n=3). *, p<0.05 vs. control.
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(Figure 2D) in Hep3B cells, despite of increased ACDase 
(Figure 1A). These results were confirmed by western blot 
in samples from Hep3B (Figure 2E) and in HepG2 cells 
(Figure 2F), paralleling the increase seen at the mRNA 
levels of GCS in both hepatoma cell lines after sorafenib 
addition. Therefore, our results indicated that the blockage 
of ceramide-modifying enzymes, particularly GCS, 
potentiates ceramide contribution to sorafenib toxicity.
GCS silencing potentiates sorafenib-induced 
toxicity in hepatoma cells
To further verify the contribution of ceramide in 
sorafenib cytotoxicity, hepatoma cells were transfected 
with siRNAs against GCS and ACDase analyzing 
sorafenib-induced cell death. GCS silencing in Hep3B 
cells, as detected by mRNA and protein levels (Figure 3A), 
Figure 2: GCS is activated by sorafenib and GCS inhibition increases sorafenib toxicity in hepatoma cells. A. and B. Cell 
viability of Hep3B cells, preincubated (30 min) with NOE (100 μM) or PDMP (30 μM), and treated with sorafenib for 16 h. C. Ceramide 
levels were quantified in Hep3B cells, preincubated with NOE and PDMP, and sorafenib for 4h. D. Time-course analysis of GCS and 
ACDase activities were analyzed in Hep3B cells treated with sorafenib (10 μM). E. and F. Hep3B and HepG2 cells, respectively, were 
treated with sorafenib and GCS protein levels measured at different times. *, p<0.05 vs. control cells. RNA interference was validated by 
qPCR and protein levels of GCS (E) and ACDase (F). Cell viability after sorafenib treatment was measured in GCS- and ACDase-silenced 
Hep3B cells, respectively, and compared to siCTRL-cells.
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elicited increased sorafenib toxicity (Figure 3B). Similarly, 
HepG2 cells transfected with GCS siRNA displayed 
higher sensitivity to sorafenib (Suppl. Fig. 3). However, 
ACDase silencing (Figure 3C), did not sensitize Hep3B 
cells sorafenib (Figure 3D), in discrepancy with the results 
observed after NOE inhibition, maybe suggesting NOE 
off-target effects. Moreover, silencing GCS in PLC cells, 
another hepatoma cell line, failed to sensitize to sorafenib 
toxicity (Suppl. Fig. 4), and this effect was accompanied 
by a modest reduction of GCS protein levels (30-40%). 
However, pharmacological inhibition of GCS with PDMP 
was highly effective in sensitizing PLC cells to sorafenib 
(Suppl. Fig. 5), although it required higher doses of 
PDMP compared to other hepatoma cell lines. Overall, 
our data suggest that blocking ceramide elimination via 
GCS reduction, rather than ACDase, improve sorafenib 
cytotoxicity in HCC cells, clearly pointing to GCS as the 
sphingolipidic enzyme to pharmacologically target for 
sorafenib combined therapy.
GCS inhibition reduced tumor growth in 
subcutaneous HCC mouse model after sorafenib 
treatment
Before starting in vivo treatments, in order to 
replicate the findings of sensitization to sorafenib upon 
GCS inhibition/silencing seen with the MTT-based 
cell viability approach, crystal violet cell proliferation 
assay was used to measure the number of viable cells. 
After four days exposure, Hep3B and HepG2 cells 
treated with PDMP were clearly sensitized to sorafenib, 
diminishing cell survival after GCS inhibition (Figure 4A), 
reproducing in clonogenic assays the findings observed 
with the MTT assay. After that, we established bilateral 
Figure 3: GCS silencing sensitizes hepatoma cells against sorafenib exposure. Hep3B cells were transfected with siRNA 
control and against GCS and ACDase. RNA interference was validated by qPCR and protein levels of GCS A. and ACDase C. Cell viability 
after sorafenib treatment was measured in GCS- and ACDase-silenced Hep3B cells (B and D, respectively) and compared to siCTRL cells. 
*, p<0.05 vs. siCTRL cells.
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xenograft tumors by injecting subcutaneously HepG2 cells 
in the flanks of nude mice. Once measurable tumors were 
established, animals received sorafenib or vehicle by oral 
gavage, with or without PDMP i.p administration. While 
sorafenib-treated mice exhibited reduced tumor growth, 
this effect was potentiated by PDMP treatment (Figure 
4B). In addition, the sensitizing effect of GCS inhibition 
by PDMP was accompanied by reduced tumor cell 
proliferation, as denoted by PCNA detection (Figure 4C) 
and vascularization, as detected in CD34 stained slides 
(Figure 4C). Moreover, we performed TUNEL assay in our 
samples to identify DNA fragmentation as consequence of 
the apoptotic cell death induced by the chemotherapeutic 
treatments (Figure 4C). Only few TUNEL positive cells 
were identified after sorafenib treatment, number that 
was slightly increased after PDMP co-treatment. In 
fact, the percentage of cells detected with fragmented 
nuclear DNA is low (under 1%), maybe suggesting that 
PDMP/sorafenib combination is not inducing classical 
apoptotic cell death. Of note, PDMP alone administration 
in mice did not modify tumor growth (Figure 4B), vessel 
formation (Figure 4C) or induce any hepatic damage 
Figure 4: GCS inhibition reduces subcutaneous tumor growth in mouse. A. Hep3B (upper) and HepG2 (lower) cells were 
treated with PDMP (0, 30 and 50 μM) and sorafenib (0, 2.5, 5 and 10 μM) for 1 day, culture medium changed, and cells allowed to grow 
for three extra days. Crystal violet staining was performed to illustrate changes in colony formation and representative images taken. B. 
Mice bearing HepG2-subcutaneous tumors were i.p. injected with PDMP (60 mg/kg) and sorafenib given orally by gavage (80 mg/kg) 
daily for 3 weeks (CTRL, n=8; PDMP, n=6; SOR+PDMP, n=8). *, p<0.05 vs. vehicle-treated mice. #, p<0.05 vs. sorafenib-treated mice. 
C. Representative images of tumor samples stained for PCNA, CD34 and TUNEL detection.
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to treated animals (data not shown). Therefore, GCS 
pharmacological inhibition was effective in increasing the 
efficacy of sorafenib therapy in mice bearing subcutaneous 
hepatoma tumors.
Effect of GCS inhibition on sorafenib-induced 
anti-proliferative effects and autophagy in 
hepatoma cells
We next explored potential mechanisms underlying 
the potentiation of SOR-induced cell death by GCS 
inhibition. Since the RAF/MEK/ERK pathway and PI3K/
AKT activity are critical in the progression of HCC [23], 
we analyzed the impact of GCS inhibition with PDMP on 
these pathways. Following sorafenib exposure, pAKT and 
pERK decreased in a dose-dependent manner in Hep3B 
cells (Figure 5A). However, no additional changes on 
PI3K/AKT and RAF/MAPK/ERK signaling pathway were 
detected after GCS inhibition.
Ceramide accumulation [24] and sorafenib 
exposure [25] have been reported to promote autophagy. 
To determine if enhanced cytotoxic effect of combined 
therapy was associated with autophagic cell death, we 
treated hepatoma cell line Hep3B with sorafenib and 
tracked the conversion of LC3-I to the LC3-II form, as an 
autophagosome marker, and p62, which is ubiquitinated 
and degraded by the autolysosomes. Sorafenib induced 
a reduction in LC3-I that was accompanied by enhanced 
degradation of p62, consistent with an increase in 
autophagy after the treatment (Figure 5B). LC3-II 
accumulation was not evident, probably because LC3-
II is also degraded by autophagy. The sorafenib/PDMP 
treatment resulted in decreased p62 levels compared to 
sorafenib alone suggesting that ceramide accumulation by 
PDMP potentiates sorafenib-induced autophagy, although 
not providing conclusive data. To further analyze this 
event, GFP-LC3 expressing Hep3B cells were cultured in 
the presence or absence of sorafenib and/or PDMP and the 
levels of punctate LC3-positive autophagosomes in cells 
were calculated in each condition [26]. As seen, sorafenib 
plus PDMP increased the number of LC3 positive dots, 
indicating enhanced autophagosome formation (Figure 5E) 
as denoted by the quantification of the percentage of cells 
with three or more autophagosomal puncta (Figure 5F).
Beclin 1 is a Bcl-2-homology domain 3 (BH3)-only 
protein required for the formation of the autophagosome, 
and Mcl1 is an anti-apoptotic Bcl-2 homolog that inhibits 
autophagy by “sequestering” Beclin 1 in a dimer [27]. 
Both proteins have a vital role in autophagy regulation in 
HCC cells [28]. Our data showed that sorafenib markedly 
decrease Mcl1 levels, and this effect is potentiated by 
PDMP (Figure 5B). In fact, Beclin 1/Mcl1 ratio increased 
from 1.0 in control cells to 2.8 in PDMP-sorafenib-treated 
cells, probably releasing Beclin 1 molecules to promote 
autophagy. In addition, we have tested for Bcl-2 and 
Bcl-xL levels after sorafenib treatment and have found 
no differences, at least at short-time incubation, which 
contrasts with the sharp decline observed for Mcl-1 levels 
as soon as 2-4 hours of sorafenib exposure (data not 
shown).
Autophagy has a dual role in cancer cells either 
promoting survival by providing nutrients to proliferating 
cells or triggering cell death via lethal mitophagy [26]. 
Moreover, GCS inhibitors have been recently described 
as enhancers of autophagy flux in primary neurons 
[29]. To address whether sorafenib plus PDMP-induced 
autophagy is protective or toxic, we incubated sorafenib/
PDMP-treated cells with 3-methyladenine (3-MA), 
inhibitor of autophagy initiation. We first tested different 
3-MA concentrations to guarantee autophagy inhibition 
in the absence of cytotoxicity to hepatoma cells. After 
that, 3-MA-induced autophagy inhibition displayed small 
protection against sorafenib alone (Figure 5C), while cell 
death was clearly potentiated by 3-MA in the combined 
treatment (Figure 5D). Therefore, sorafenib/PDMP-
induced autophagy induction seems to act as a protective 
mechanism, discarding autophagy-induced cell death as 
the mechanism triggered during PDMP/sorafenib toxicity.
GCS inhibition triggers mitochondrial-
dependent cell death by sorafenib in 
hepatoma cells
Besides its involvement in autophagy regulation, 
Mcl1 is an antiapoptotic mitochondrial Bcl-2 member, 
suggesting that the sensitization of PDMP to sorafenib 
could involve apoptotic cell death. Mitochondrial damage 
results from sorafenib interaction with mitochondrial 
respiratory chain and reactive oxygen species 
(ROS) production [30]. Similarly, ceramide induces 
mitochondrial permeability after direct interaction with 
complex III of the respiratory system [31]. Moreover, 
sphingolipids, and particularly ceramide, promote changes 
in mitochondrial membrane composition favoring channel 
formation by Bcl-2 family members [32, 33]. Therefore, 
we evaluated the influence of GCS inhibition on ROS 
production and mitochondrial membrane potential (MMP) 
after sorafenib treatment. Hep3B cells were treated with 
sorafenib and/or PDMP and incubated for 30 minutes 
with DCF to determine ROS production and with JC-1 
to estimate MMP. Sorafenib induced a rapid decline in 
MMP even at low doses, which was not modified by 
PDMP addition (Figure 6A). In fact, dissipation of MMP 
was complete in less than 30 minutes with sorafenib 
doses over 10 μM (not shown here), while PDMP alone 
had no affect. In parallel, ROS induction caused by 
sorafenib was not potentiated by PDMP, as measured 
fluorimetrically by DCF (Figure 6B). In line with these 
observations, we addressed whether sorafenib-induced 
mitochondrial complex I inactivation, as observed 
in human neuroblastoma cells [30] is potentiated by 
sorafenib. Complex I activity decreased in sorafenib-
treated hepatoma cells (around 50%), but PDMP co-
addition did not significantly modify it (Suppl. Fig. 6).
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Figure 5: Signaling changes after GCS inhibition in sorafenib treated hepatoma cells. A. Protein levels of ERK and AKT 
phosphorylation in Hep3B cells after 16 h exposure to increasing doses of sorafenib (2.5, 5, 10 μM) with or without PDMP (30 μM, 4 h) for 
4 h. B. Expression levels of Mcl1, Beclin 1, p62 and LC3 were analyzed by Western blot and β-actin used as a loading control. Bafilomycin 
A1 (Baf, 0.1 μM) was used as autophagy inhibitor. C. and D. Cell viability of Hep3B cells pretreated (30 min) with autophagy inhibitor 
(3MA, 2 μM) or pancaspase inhibitor Z-VAD-FMK (ZVAD, 25 μM) before sorafenib/PDMP exposure for 16 hours. *, p<0.05 vs. control 
Hep3B cells. E. Hep3B cells expressing GFP-LC3 were treated with sorafenib and/or PDMP and representative images were taken 6 
hours later. F. Wide-field pictures were taken and the number of GFP-LC3-positive autophagosomes per cell was counted in 100 cells per 
condition. Hep3B cells exhibiting three or more green puncta per cell were considered positive. *, p<0.05 vs. control Hep3B cells. #, p<0.05 
vs. sorafenib Hep3B cells.
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Interestingly, despite the lack of changes in ROS 
and MMP by GCS inhibition in sorafenib-treated HCC 
cells, combined drug treatment enhanced the release of 
cytochrome c into the cytosol (Figure 6C), indicative of 
mitochondrial outer membrane permeabilization. Of note, 
neither sorafenib (1-10 μM) nor PDMP alone up to 6-8 
hours exposure induced cytochrome c release, although 
sorafenib alone at doses higher than 10 μM triggered 
cytochrome c translocation in O/N experiments (not 
shown here).
Since mitochondrial cytochrome c release frequently 
triggers caspase-dependent cell death through activation 
of executor caspases, we measured caspase-3 levels 
compared to TNF plus cycloheximide. Sorafenib increased 
caspase-3 activity modestly in hepatoma cells, that was 
not further enhanced by PDMP addition (Figure 6D), 
despite the induction of cytochrome c release and cell 
death. Notably, sorafenib/PDMP-induced cell death was 
not blocked by pre-incubation with a pan caspase inhibitor 
ZVAD (Figure 5D), at doses previously verified to block 
Fas-induced apoptosis [17], further suggesting that the 
mechanism involved in PDMP sensitization is caspase-
independent.
Elevation of glycolysis and enhanced autophagy may 
cooperate to protect cells from caspase independent cell 
death [28], preserving viability even after decline of MMP. 
Release of mitochondrial intermembrane proteins such as 
cytochrome c induces a rapid loss of activity in respiratory 
complexes jeopardizing mitochondrial functionality, and 
leading to bioenergetic crisis and cell death [34]. To test 
if GCS inhibition triggers this mechanism, we determined 
changes in ATP concentration on sorafenib/PDMP exposed 
cells. While neither sorafenib nor GCS inhibition reduced 
ATP levels in Hep3B cells, the combination sorafenib/
PDMP depleted ATP levels (Figure 6E), suggesting the 
induction of mitochondrial collapse by GCS inhibition 
in sorafenib-treated cells. To discard that this effect was 
caused by a decline in the number of mitochondria as a 
consequence of the treatments, we examined for changes 
in the mitochondrial DNA copy number in cells [35]. 
Despite the mitochondrial dysfunction observed after 
6 hours following sorafenib/PDMP administration, no 
alteration in mitochondrial DNA amount was detected 
indicating that a decrease in mitochondrial mass was not 
the reason for the mitochondrial alteration (Suppl. Fig. 7).
Moreover, although most tumors exhibit a 
preferential switch to glycolysis, ceramide may reduce 
GAPDH expression targeting the “Warburg effect”, as 
observed in melanoma cells [36]. However, sorafenib did 
not change GAPDH expression regardless of the presence 
of PDMP (Suppl. Fig. 8), suggesting a mitochondrial 
contribution in the ATP decline caused by the PDMP/
sorafenib cotreatment. Moreover, GCS inhibition 
in sorafenib-treated cells caused significant nuclear 
Figure 6: GCS inhibition induces cytochrome c release and ATP depletion to sorafenib-treated hepatoma cells. A. 
Mitochondrial membrane potentialby JC1determination and B. ROS production by DCF quantification was determined in Hep3B cells 
exposed to sorafenib (10 μM) and PDMP (50 μM). C. cytochrome c levels in cytosol (C) and mitochondria (M) were analyzed by western 
blot in cell extracts from sorafenib/PDMP treated cells. D. Fold increase in caspase 3 activity was determined in total cell extracts as above, 
and TNF (50 ng/ml) plus cycloheximide (40 μM) used as a positive control (+). E. and F. ATP levels were measured in Hep3B cells treated 
with sorafenib and compared to sorafenib+PDMP combination. *, p<0.05 vs. control Hep3B cells. #, p<0.05 vs. sorafenib-treated Hep3B 
cells. F. Nuclear Hoechst staining was visualized in Hep3B cells treated with sorafenib and/or PDMP.
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condensation (12.7±2.5, 8 hours), detected by Hoechst 
staining (Figure 6F), compared to sorafenib (2.3±0.7%) 
or PDMP (1.6±0.7%) alone, without evidences of 
fragmented nuclei on later times of incubation (data not 
shown). Apparently, since executioner caspases require 
for full apoptotic death a non-oxidative environment and 
an operational ATP production, in sorafenib/PDMP treated 
cells, despite cytochrome c release, caspase activation is 
blocked forcing the cell to die by a caspase-independent 
mechanism after mitochondrial collapse. However, to 
better characterize this event a complete bioenergetic 
study with a flux analyzer would be required.
Hepatoma cell lines exhibit acquired sorafenib-
resistance and high GCS expression after long-
time exposure to sorafenib
The systemic treatment with sorafenib in patients 
with advanced HCC results in limited survival benefits 
suggesting the existence of primary and acquired drug 
resistance mechanisms [4–6]. To evaluate if GCS 
overexpression may participate in sorafenib-resistant 
phenotype, Hep3B and HepG2 cells were grown during 
12 months in the presence of sorafenib (0-5 μM) leading to 
sorafenib resistance (Figure 7A-7B). Of note, before MTT 
assays, hepatoma cells chronically exposed to sorafenib 
were maintained in culture medium without sorafenib 
for a week before assays. Moreover, hepatoma resistant 
cells displayed almost no reduction in ERK signaling 
after sorafenib exposure, in opposition to sensitive cells, 
while exhibiting resistance for more than one month 
after sorafenib withdrawal and cross-resistance to other 
chemotherapeutic agents, such as doxorubicin (data 
not shown). Afterwards, we checked for alterations in 
the sphingolipid metabolism after long-term sorafenib 
administration in hepatoma cells. While short-time 
sorafenib addition stimulated mRNA changes in several 
sphingolipidic enzymes (Table 1), Hep3B cells with 
acquired sorafenib resistance exhibited modifications 
only in very specific sphingolipidic proteins (Table 2), 
most prominently in GCS expression. An effect also 
observed in HepG2 resistant cells (Suppl. Table 2). To 
validate if GCS expression could play a role in sorafenib 
resistance, we reduced GCS levels by RNA interference. 
Figure 7: Sorafenib-resistant hepatoma cells were re-sensitized to sorafenib exposure by GCS targeting in vitro and 
in tumor mouse model. A. and B. dose-response analysis by MTT in Hep3B and HepG2 cells after long-term drug exposure. C. Cell 
viability of Hep3B R cells after transfection with siRNA against GCS (siGCS) or control (siCTRL) and sorafenib exposure. Representative 
image of protein levels in upper panel. *, p<0.05 vs. siCTRL Hep3B cells. D. Hep3B cells transfected with vector control (PCMV6-XL5) 
or GCS-PCMV6-XL5, with protein levels shown in upper panel, were exposed to sorafenib and cell viability determined. *, p<0.05 vs. 
sorafenib-sensitive (S) hepatoma cells. E. and F. Representative image of sorafenib-resistant HepG2 subcutaneous tumors after 4 weeks 
of treatment with vehicle (CTRL), sorafenib and/or GCS inhibitor (PDMP), and graphical representation of tumor volumes (CTRL, n=6; 
PDMP, n=5; SOR, n=12; SOR+PDMP, n=11). *, p<0.05 vs. sorafenib-treated (SOR) tumors.
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Sorafenib-resistant Hep3B cells (Hep3B R cells) 
transfected with siRNA against GCS displayed increased 
sensitivity upon sorafenib administration (Figure 7C). 
Moreover, pharmacological inhibition of GCS with PDMP 
was effective in reducing sorafenib resistant in Hep3B R 
cells dose-dependently (Suppl. Fig. 9). Similar results were 
also observed in HepG2 resistant cells (Suppl. Fig. 10). 
To further verify this observation, we overexpressed GCS 
in Hep3B cells before exposure to sorafenib (Figure 7D). 
GCS-transfected Hep3B cells displayed reduced sorafenib-
induced cell death, suggesting that GCS mediates, at least 
partially, sorafenib-acquired resistance in hepatoma cells.
Therefore, since our results indicated that GCS 
overexpression could contribute to the inefficacy of 
sorafenib-therapy, we addressed if enhanced expression of 
GCS also occurs in tumors from HCC patients. To do so, 
we measured GCS mRNA levels in a human cDNA array 
from normal liver tissue or individuals with different HCC 
staging. Our results did not detect changes in GCS levels 
depending on the HCC stage (Suppl. Fig. 11), probably 
indicating a relevant role of GCS in cancer-resistance 
rather than in tumor progression or invasiveness.
Sorafenib-resistant HepG2 xenografts tumors 
displayed sorafenib sensitivity after GCS 
inhibition
Enhanced metastatic potential of hepatoma cells 
with sorafenib resistance has been previously reported in 
an orthotopic HCC model [37]. In our experiments, we 
did not detected differences in terms of multiplicity or 
engraftment between sorafenib-resistant HepG2 tumors 
compared to mice inoculated with parental HepG2 cells. 
Once developed, animals were randomly divided in groups 
and treated with sorafenib or vehicle in combination with 
GCS inhibitor PDMP. Our results verified tumor sorafenib 
resistance during the study, while the combined therapy 
(PDMP plus sorafenib) significantly reduced the growth of 
resistant tumors (Figure 7E-7F). Of note, GCS inhibition 
alone did not affect tumor volume (Figure 7F), and did 
not cause any detectable liver damage alone or combined 
with sorafenib (data not shown). In conclusion, GCS 
antagonism restored tumor sensitivity to sorafenib in vivo, 
suggesting GCS targeting as an interesting strategy against 
sorafenib-acquired resistance.
DISCUSSION
Sorafenib is the only approved systemic drug 
recommended for HCC patients with recurrence after 
resection/ablation or diagnosed at advanced stages [38, 
39]. Although other molecular therapies, tested head-to-
head versus sorafenib, are explored in phase III clinical 
trials, none of them have achieved superior results [4–6]. 
Therefore, despite its limitations, sorafenib is so far the 
best option for advanced HCC and the first drug able 
to disclose a weakness in HCC biology likely due to its 
targeting of multiple pathways. Further research is needed 
to identify novel molecular targets, but efforts to explore 
the efficacy of combination therapies with sorafenib 
should not be obviated. In this sense, our data reveals 
that ceramide metabolism is activated during sorafenib 
administration, making plausible strategies in HCC 
treatment aimed to increase cytotoxicity via ceramide 
accumulation, by targeting specific ceramide-degrading 
enzymes such as GCS. Importantly, GCS is overexpressed 
in sorafenib resistant hepatoma cells after long term 
exposure, pointing to GCS induction as a specific mediator 
of sorafenib resistance that provides a potential target for 
cancer therapy.
Most common mutations in HCC, such as p53 
and beta-catenin, are undruggable, therefore, suggesting 
the need to exploit the use of proteins with well-known 
inhibitors such as GCS to improve HCC management. 
In this sense, PDMP [40], is a well characterized GCS 
inhibitor and has served as a basis of novel GCS inhibitors, 
Table 2: mRNA levels of main sphingolipidic enzymes in sorafenib-resistant and sensitive Hep3B cells 
 Hep3B S Hep3B R
ASMase 1.00±0.25 0.97±0.10
NSMase 1.00±0.22 1.12±0.22
ACDase 1.00±0.11 1.04±0.37
NCDase 1.00±0.18 0.98±0.23
CerS2 1.00±0.15 1.20±0.19
CerS4 1.00±0.27 1.05±0.29
GCS 1.00±0.09 4.28±0.38 *
SPT 1.00±0.16 1.17±0.13
SK1 1.00±0.25 1.90±0.29 *
Ceramide-related enzymes were analyzed by RT-PCR in Hep3B cells that exhibit sorafenib resistance after long-term 
exposure to sorafenib (Hep3B R) or vehicle (Hep3B S). (n=3). *, p<0.05 vs. control.
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which are now tested in clinical trials. Particularly, 
eliglustat tartrate, a PDMP derivative designed for the 
treatment of lysosomal diseases [41], have recently 
reached FDA approval for Gaucher’s disease patients 
[42]. Obviously, confirmation in preclinical models would 
be required, but it is tempting to speculate about positive 
results with immediate medical application.
Compounds that potentiates sorafenib efficacy are 
important since validate potential targets, and also provide 
clues for other products acting in the same metabolic 
pathway or in the same subcellular location. In this sense, 
our work points to the mitochondria as the organelle 
where sorafenib toxicity is triggered by PDMP addition. 
Several reports indicate that sorafenib interferes with 
the mitochondrial respiratory machinery, inducing loss 
of membrane potential and ROS production. However, 
our data shows that sorafenib-treated cells maintained 
mitochondrial integrity, without any loss of cytochrome 
c, and with relatively normal ATP levels for several hours. 
In fact, autophagy induction and the capacity of tumor 
cells of generating ATP from extra-mitochondrial source 
via glycolysis (Warburg effect) are adaptive mechanisms 
that allow tumor recovering after strong mitochondrial 
damage, sometimes from only a small fraction of surviving 
mitochondria [43]. It is conceivable that sorafenib is 
acting similarly in the absence of other mitochondrial-
damaging stimuli, being insufficient to cause death in 
most hepatoma cells. In fact, recent data indicates that the 
mitochondrial damage induce by sorafenib is accompanied 
by progressive glycolytic reprogramming to help cells 
to survive under energetic stress [44]. Regarding this 
point, we cannot rule out that GCS inhibition may be 
also blocking the glycolytic pathway of ATP generation, 
such as observed in chronic lymphocytic leukemia 
treated with nanoliposomal ceramide [36]. However, we 
detected no reduction in GADPH activity after PDMP/
sorafenib treatment. In line with these finding, our data 
support a pathway in which GCS inhibition leading to 
increase ceramide levels targets mitochondria, inducing 
cytochrome c release, loss of ATP and energetic collapse, 
making hepatoma cells incapable of recovery and destined 
to die.
Numerous publications have shown how ceramide 
accumulation perturbs the mitochondrial integrity 
[13, 16, 14, 31–33], similarly to our observations in 
sorafenib-treated hepatoma cells. In particular, changes in 
sphingolipid composition of the mitochondrial membranes 
seem to alter the specific lipid milieu required for Bak/
Bax activation modifying the cell death induced by BH3-
only proteins [32, 33]. Therefore, it is plausible that 
molecules, such as specific Bcl-2 inhibitors, could elude 
the incomplete MMP induced by sorafenib by breaking 
the resistance at the point of Bax or Bak activation, as 
observed in the PDMP/sorafenib combination. In line 
with this, Bcl-xL inactivation (ABT-737) in combination 
with sorafenib, that down-regulates Mcl-1 expression 
specifically in tumor cells, efficiently induced cell 
death in hepatoma cells [45]. In fact, a recent report has 
shown in vinorelbine-resistant lung adenocarcinoma 
cells an increase in GCS activity which was associated 
with induction of Bcl-xL-mediated cell survival [46]. 
Interestingly, this is not the only link established between 
ceramide metabolism and Bcl-2 protection. A recent 
publication proposes a feed-forward model by which BAK 
activation by chemotherapeutic drugs, and particularly by 
BH3 mimetics, leads to elevated ceramide levels resulting 
in synergistic channel formation by ceramide metabolites 
and BAX/BAK. Certainly, if this mechanism is induced 
by the combination of sorafenib and Bcl-2 mimetics is a 
point that deserves further investigation [47]. In fact, it 
is possible that other mitochondrial interfering molecules 
may potentiate sorafenib efficacy maybe due to the 
dependence on mitochondrial biogenesis of cancer stem 
cells survival [48]. Accordingly, our results point to GCS 
targeting as an interesting approach to increase sorafenib 
efficacy in HCC management, and support strategies 
aiming mitochondria to improve sorafenib therapy.
MATERIALS AND METHODS
Cell culture and conditioned medium 
preparation
Human liver tumor cell lines Hep3B, PLC and 
HepG2 (European Collection of Animal Cell Cultures 
(ECACC)) were grown in DMEM (10% FBS) at 37°C 
and 5% CO2. To generate sorafenib-resistant hepatoma 
cells, freshly thawed Hep3B and HepG2 cells were 
cultured with 1 μM of sorafenib and, after a month, the 
concentration slowly increased by 0.5 μM per month (up 
to 5 μM). After 8 to 10 months, two sorafenib-resistant cell 
lines, termed HepG2 R and Hep3B R, were obtained. The 
LD50 of the cells to sorafenib was determined in 96-well 
plates, routinely for 24 hours and cell viability measured 
by MTT assay.
qPCR and Immunoblot analysis
Total DNA isolated with and total RNA with TRIzol 
reagent were analyzed with SensiFAST SYBR One-Step 
Kit (Bioline. Ecogen, Barcelona, Spain) following the 
manufacturer’s instructions, as detailed in Supplemental 
Methods. Western blots were performed as indicated in 
Supplemental Methods.
RNA interference and GCS overexpression
HepG2 and Hep3B cells were transfected with 
siRNAs, designed to knockdown gene expression of 
GCS, ACDase or control (siGCS, sc-45404; siACD, sc-
105032; siCTRL, sc-37007, Santa Cruz Biotechnologies), 
or with GCS-expressing or PCMV6-XL5 control vectors 
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(Origene, Rockville, MD, USA). RNA silencing or GCS 
overexpression were verified by western blot and qPCR, 
as detailed in Supplemental Methods.
Biochemical analysis
Cell viability, clonogenic assays, Hoechst staining, 
caspase-3 activity, mitochondrial membrane potential 
(MMP), reactive oxygen species (ROS) production [17], 
mitochondrial DNA content, mitochondrial Complex I 
activity, GAPDH expression and ATP levels were analyzed 
as explained in Supplemental Methods. Ceramide 
determination after [14C]palmitic acid labeling, and GCS/
ACDase activities were performed as previously described 
[13, 18], and detailed in Supplemental Methods.
Tumor animal model
All animal procedures were performed according 
to protocols approved by the Animal Experimentation 
Ethics Committee from the University of Barcelona. 
For subcutaneous tumor model, male Swiss nude mice, 
5-6 week old, were kept under pathogen-free conditions 
with free access to standard food and water. HepG2 
cells (5×106) or Hep3B cells (2.5×106) were injected 
subcutaneously into the flanks of mice in 200 μL DMEM 
without FBS, as previously reported [13, 19]. Treatment 
with GCS inhibitor 1-phenyl-2-decanoylamino-3-
morpholino-1-propranol (PDMP) or vehicle (saline 
solution) was delivered i.p. daily, while sorafenib was 
administered via oral gavage at a dose of 80 μg/g body 
weight for 21 days. Tumors were measured periodically 
with a vernier caliper, and the volume was calculated as 
length×width2×0.5.
Immunohistochemical staining
Tumors were fixed and 5-μm sections were prepared 
following standard procedures. The antibodies used were 
mAb anti-PCNA antibody (PC10) (1:200, sc-56, Santa 
Cruz) and anti-CD34 (1:100, sc-18917, Santa Cruz). The 
slices were examined with a Zeiss Axioplan microscope 
equipped with a Nikon DXM1200F digital camera. PCNA 
index was quantified in four randomly selected fields from 
each animal, and CD34 positive areas analyzed using 
ImageJ software. Apoptotic cells with fragmented nuclei 
were detected in paraffin samples using TUNEL labeling 
containing fluorescein-dUTP and -dNTPs (TUNEL Label 
Mix, Roche). TUNEL positive cells were observed and 
quantified using a NIKON Eclipse E-100 microscope.
Statistical analyses
Results are expressed as mean ± standard deviation 
and n=3, unless indicated. Statistical comparisons were 
performed using unpaired 2-tailed Student’s t test or 
1-way ANOVA followed by Newman-Keuls Multiple 
Comparison Test (GraphPad Prism). A P value less than 
0.05 was considered significant.
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